Amneal Pharmaceuticals (NYSE:AMRX – Get Free Report) issued an update on its FY 2023 earnings guidance on Friday morning. The company provided EPS guidance of $0.45-$0.55 for the period, compared to the consensus EPS estimate of $0.47. The company issued revenue guidance of $2.30 billion-$2.40 billion, compared to the consensus revenue estimate of $2.32 billion. […]

Related Keywords

Piper Sandler , Barclays , Amneal Pharmaceuticals Price Performance , Amneal Pharmaceuticals Company Profile , Neuberger Berman Group , Amneal Pharmaceuticals Inc , Blackrock Inc , Vanguard Group Inc , Amneal Pharmaceuticals , Institutional Trading Of Amneal Pharmaceuticals , Morgan Stanley , Millennium Management , News Ratings For Amneal Pharmaceuticals Daily , Get Free Report , Moderate Buy , Berman Group , Amneal Pharmaceuticals Daily , Nyse Amrx , Amrx , Medical , Guidance , Earnings , Preannouncement ,